Advances in clinical detection methods and nanomaterials for autoimmune liver diseases
Nano TransMed · 2023
DOI: 10.1016/j.ntm.2023.100003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano TransMed, 2023. Verfasst von Jingjing Chen und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Autoimmune liver disease (AILD) is a kind of chronic liver disease, due to the autoimmune tolerance of the liver break-down, as well as the imbalance of immune cell numbers and functions led to persistent inflammatory damage of the liver. With the rapid development of diagnoses and treatments, the proportion of liver diseases has changed significantly. Autoimmune liver diseases have gradually become one of the focuses of scholars worldwide. The specificity and sensitivity of diagnostic and prognostic evaluation methods of AILD have always been social concerns of the researchers owing to the variety of etiology, incompletely understood pathogenesis and different clinical phenotypes. This article reviews the current research status and summarizes the research advances and nanomaterials of the diagnosis and prognosis evaluation methods of AILDs.
Zitieren
APA
Chen, J., Zhu, Y., Wang, Q., Ding, J., & Chen, X. (2023). Advances in clinical detection methods and nanomaterials for autoimmune liver diseases. Nano TransMed. https://doi.org/10.1016/j.ntm.2023.100003
Vancouver
Chen J, Zhu Y, Wang Q, Ding J, Chen X. Advances in clinical detection methods and nanomaterials for autoimmune liver diseases. Nano TransMed. 2023. doi:10.1016/j.ntm.2023.100003
BibTeX
@article{Chen2023,
author = {Chen, Jingjing and Zhu, Yaqi and Wang, Qingcui and Ding, Jinya and Chen, Xiaohua},
title = {Advances in clinical detection methods and nanomaterials for autoimmune liver diseases},
journal = {Nano TransMed},
year = {2023},
doi = {10.1016/j.ntm.2023.100003}
}
EUVIMED